Hemophilia market forecast 2014-2023.
By Natasha Spiller, Analyst
22 May 2014
I am an Analyst at Datamonitor Healthcare. After joining the company in 2012, I have produced analysis across a number o...
Read full bio
This webinar evaluates key marketed and pipeline brands for the treatment of hemophilia.
The lucrative hemophilia market, worth an estimated $10bn in the US, Japan, and five major EU markets in 2014, will continue to expand over the next ten years.
This webinar examines the dynamics that will contribute to the market’s growth, including the emergence of long-acting therapies for hemophilia A and B, and the growing use of prophylactic treatment regimens.
Get the answers to these questions:
- What is the value of the hemophilia market and how is this set to change over the next ten years?
- How will long-acting therapies compete with existing marketed brands in the treatment of hemophilia A and B?
- How will hemophilia therapy change following a surge in the number of treatment options?
Posted in Cardiovascular.